Minimally invasive cell-seeded biomaterial systems for injectable/epicardial implantation in ischemic heart disease

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5969-5994

  Ravichandran, Rajeswari ^a   Venugopal, Jayarama Reddy ^a   Sundarrajan, Subramanian ^a   Mukherjee, Shayanti ^a   Ramakrishna, Seeram ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biomaterials; Cardiac tissue engineering; Injectable system; Myocardial infarction

Indexed keywords

ALGINIC ACID; BIOMATERIAL; CHITOSAN; COLLAGEN; FIBRIN; MATRIGEL; RECOMBINANT EPIDERMAL GROWTH FACTOR; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; RECOMBINANT SOMATOMEDIN C; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT VASCULOTROPIN; TRANSFORMING GROWTH FACTOR ALPHA; TISSUE SCAFFOLD;

ADIPOSE DERIVED STEM CELL; BIOCOMPATIBILITY; BONE MARROW CELL; CARDIAC IMPLANT; CARDIAC STEM CELL; CARDIOVASCULAR THERAPEUTIC DEVICE; CELL DIFFERENTIATION; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYDROGEL; INJECTION; LEFT VENTRICULAR RESTRAINT DEVICE; MESENCHYMAL STEM CELL TRANSPLANTATION; MINIMALLY INVASIVE PROCEDURE; MYOBLAST; PLURIPOTENT STEM CELL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REGENERATION; VENTRICULAR ASSIST DEVICE; ANIMAL; CELL CULTURE; HEART MUSCLE ISCHEMIA; HUMAN; INSTRUMENTATION; INTRALESIONAL DRUG ADMINISTRATION; METHODOLOGY; MINIMALLY INVASIVE SURGERY; PERICARDIUM; TRANSPLANTATION;

ANIMALS; CELLS, CULTURED; GUIDED TISSUE REGENERATION; HUMANS; INJECTIONS, INTRALESIONAL; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; PERICARDIUM; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84875838006     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S37575     Document Type: Review

References (232)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
2. Baig MK, Mahon N, McKenna WJ, et al. The pathophysiology of advanced heart failure. Heart Lung. 1999;28:87-101.
3. Sarig U, Machluf M. Engineering cell platforms for myocardial regeneration. Expert Opin Biol Ther. 2011;11:1055-1077.
4. Tous E, Purcell BP, Ifkovits JL, Burdick JA. Injectable acellular hydrogels for cardiac repair. J Cardiovasc Transl Res. 2011;4:528-542.
5. Rane AA, Christman KL. Biomaterials for the treatment of myocardial infarction a 5-year update. J Am Coll Cardiol. 2011;58:2615-2629.
6. Nunes SS, Song H, Chiang CK, Radisic M. Stem cell-based cardiac tissue engineering. J Cardiovasc Transl Res. 2011;4:592-602.
7. Beitnes JO, Lunde K, Brinchmann JE, Aakhus S. Stem cells for cardiac repair in acute myocardial infarction. Expert Rev Cardiovasc Ther. 2011;9:1015-1025.
8. Chiu LL, Iyer RK, Reis LA, Nunes SS, Radisic M. Cardiac tissue engineering:current state and perspectives. Front Biosci. 2012;17: 1533-1550.
9. LeGrice IJ, Smaill BH, Chai LZ, Edgar SG, Gavin JB, Hunter PJI. Laminar structure of the heart: ventricular myocyte arrangement and connective tissue architecture in the dog. Am J Physiol. 1995;269: H571-H582.
10. Smaill BH, Hunter PJ. Theory of Heart. New York, NY: Springer-Verlag; 1991.
11. Goldsmith EC, Hoffman A, Morales MO, et al. Organization of fibro-blasts in the heart. Dev Dyn. 2004;230:787-794.
12. Eghbali M, Blumenfeld OO, Seifter S, et al. Localization of types I, III, IV collagen mRNAs in rat heart cells by in situ hybridization. J Mol Cell Cardiol. 1989;21:103-113.
13. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol. 2003;200:423-428.
14. Bing OH, Ngo HQ, Humphries DE, et al. Localization of alpha1(I) collagen mRNA in myocardium from the spontaneously hypertensive rat during the transition from compensated hypertrophy to failure. J Mol Cell Cardiol. 1997;29:2335-2344.
15. Robinson TF, Geraci MA, Sonnenblick EH, Factor SM. Coiled perimysial fibers of papillary muscle in rat heart: morphology, distribution, and changes in configuration. Circ Res. 1988;63:577-592.
16. Borg TK, Johnson LD, Lill PH. Specific attachment of collagen to cardiac myocytes: in vivo and in vitro. Dev Biol. 1983;97:417-423.
17. Chang AC, Towbin JA. Heart Failure in Children and Young Adults: From Molecular Mechanisms to Medical and Surgical Strategies. Philadelphia, PA: Saunders Elsevier; 2006.
18. Zimmermann WH, Didie M, Doker S, et al. Heart muscle engineering: an update on cardiac muscle replacement therapy. Cardiovasc Res. 2006;71:419-429.
19. Zimmermann WH, Melnychenko I, Wasmeier G, et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med. 2006;12:452-458.
20. Torrent-Guasp F, Ballester M, Buckberg GD, et al. Spatial orientation of the ventricular muscle band: physiologic contribution and surgical implications. J Thorac Cardiovasc Surg. 2001;122:389-392.
21. McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365: 1877-1889.
22. Packer M. The impossible task of developing a new treatment for heart failure. J Card Failure. 2002;8:193-196.
23. Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-Sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant. 2009;28: 1007-1022.
24. Smith RR, Barile L, Messina E, Marban E. Stem cells in the heart: what's the buzz all about? Part 2: arrhythmic risks and clinical studies. Heart Rhythm. 2008;5:880-887.
25. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3:1-5.
26. Kelley ST, Malekan R, Gorman JH, et al. Restraining infarct expansion preserves left ventricular geometry and function after acute anteroapical infarction. Circulation. 1999;99:135-142.
27. Chaudhry PA, Mishima T, Sharov VG, et al. Passive epicardial con-tainment prevents ventricular remodeling in heart failure. Ann Thorac Surg. 2000;70:1275-1280.
28. Walsh RG. Design and features of the Acorn CorCap Cardiac Support Device: the concept of passive mechanical diastolic support. Heart Fail Rev. 2005;10:101-107.
29. Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol. 2006;48:907-913.
30. Klodell CT Jr, Aranda JM Jr, McGiffin DC, et al. Worldwide surgical experience with the Paracor HeartNet cardiac restraint device. J Thorac Cardiovasc Surg. 2008;135:188-195.
31. Li RK, Jia ZQ, Weisel RD, Mickle DA, Choi A, Yau TM. Survival and function of bioengineered cardiac grafts. Circulation. 1999;100: II63-II169.
32. Leor J, Aboulafia-Etzion S, Dar A, et al. Bioengineered cardiac grafts: a new approach to repair the infarcted myocardium? Circulation. 2000;102:III56-III61.
33. Kofidis T, de Bruin JL, Hoyt G, et al. Myocardial restoration with embryonic stem cell bioartificial tissue transplantation. J Heart Lung Transplant. 2005;24:737-744.
34. Zimmermann WH, Didie M, Wasmeier GH, et al. Cardiac grafting of engineered heart tissue in syngenic rats. Circulation. 2002;106: I151-I157.
35. Tulloch NL, Muskheli V, Razumova MV, et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res. 2011;109:47-59.
36. Fujimoto KL, Tobita K, Merryman WD, et al. An elastic, biodegradable cardiac patch induces contractile smooth muscle and improves cardiac remodeling and function in subacute myocardial infarction. J Am Coll Cardiol. 2007;49:2292-2300.
37. Yamada N, Okano T, Sakai H, Karikusa F, Sawasaki Y, Sakurai Y. Thermo-responsive polymeric surfaces; control of attachment and detachment of culture cells. Macromol Chem Rapid Commun. 1990;11: 571-576.
38. Okano T, Yamada N, Sakai H, Sakurai Y. A novel recovery system for cultured cells using plasma-treated polystyrene dishes grafted with poly(N-isopropylacrylamide). J Biomed Mater Res. 1993;27: 1243-1251.
39. Guo XM, Zhao YS, Chang HX, et al. Creation of engineered cardiac tissue in vitro from mouse embryonic stem cells. Circulation. 2006;113: 2229-2237.
40. Shimizu T, Yamato M, Isoi Y, et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res. 2002;90:e40-e48.
41. Zhang P, Zhang H, Wang H, Wei Y, Hu S. Artificial matrix helps neonatal cardiomyocytes restore injured myocardium in rats. Artif Organs. 2006;30:86-93.
42. Sekiya S, Shimizu T, Yamato M, Kikuchi A, Okano T. Bioengineered cardiac cell sheet grafts have intrinsic angiogenic potential. Biochem Biophys Res Commun. 2006;341:573-582.
43. Radisic M, Deen W, Langer R, Vunjak-Novakovic G. Cardiac muscle tissue engineering: toward an in vitro model for electrophysiological studies. Am J Physiol Heart Circ Physiol. 2005;288:1278-1289.
44. Ravichandran R, Venugopal JR, Sundarrajan S, Mukherjee S, Ramakrishna S. Poly(glycerol sebacate)/gelatin core/shell fibrous structure for regeneration of myocardial infarction. Tissue Eng Part A. 2011;17:1363-1373.
45. Wang Y, Ameer GA, Sheppard BJ, Langer R. A tough biodegradable elastomer. Nat Biotechnol. 2002;20:602-606.
46. Chen QZ, Bismarck A, Hansen U, et al. Characterisation of a soft elastomer poly(glycerol sebacate) designed to match the mechanical properties of myocardial tissue. Biomaterials. 2008;29(1):47-57.
47. Ravichandran R, Venugopal JR, Sundarrajan S, Mukherjee S, Sridhar R, Ramakrishna S. Expression of cardiac proteins in neonatal cardiomyocytes on PGS/fibrinogen core/shell substrate for cardiac tissue engineering. Int J Cardiol. Epub May 5, 2012.
48. Mukherjee S, Venugopal JR, Ravichandran R, Ramakrishna S, Raghunath M. Evaluation of the biocompatibility of PLACL/ collagen nanostructured matrices with cardiomyocytes as a model for the regenera-tion of infarcted myocardium. Adv Funct Mater. 2011;21:2291-2300.
49. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracel-lular microenvironments for morphogenesis in tissue engineering. Nat Biotechnol. 2005;23:47-55.
50. Ravichandran R, Liao S, Ng CCH, Chan CK, Raghunath M, Ramakrishna S. Effects of nanotopography on stem cell phenotypes. World J Stem Cells. 2009;1:55-66.
51. Leor J, Amsalem Y, Cohen S. Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol Ther. 2005;105:151-163.
52. Ravichandran R, Venugopal JR, Sundarrajan S, Mukherjee S, Sridhar R, Ramakrishna S. Minimally invasive injectable short nanofibers of poly(glycerol sebacate) for cardiac tissue engineering. Nanotechnology. 2012;23:385102.
53. Murry CE, Field LJ, Menasché P. Cell-based cardiac repair: reflections at the 10-year point. Circulation. 2005;112:3174-3183.
54. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal myo-blast transplantation for repair of myocardial necrosis. J Clin Invest. 1996;98:2512-2523.
55. Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428:664-668.
56. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modi-fied with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9:1195-1201.
57. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114: 763-776.
58. Doss MX, Koehler CI, Gissel C, Hescheler J, Sachinidis A. Embryonic stem cells: a promising tool for cell replacement therapy. J Cell Mol Med. 2004;8:465-473.
59. Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation. 2009;120:408-416.
60. Wu KH, Liu YL, Zhou B, Han ZC. Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells. Eur J Cardiothorac Surg. 2006;30:770-781.
61. Fukada J, Kurimoto Y, Ruiz P, et al. Long-term survival of rat cardiac allografts by intrathymic plus portal venous injections of donor bone marrow cells and short-term tacrolimus immunosuppression. Transpl Int. 2001;14:311-319.
62. Hamano K, Nishida M, Hirata K, et al. Local implantation of autolo-gous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease: clinical trial and preliminary results. Jpn Circ J. 2001;65:845-847.
63. Gao LR, Tang CS, Zhu ZM, et al. The autologous bone marrow mono-nuclear cell transplantation by intracoronary route treat patients with severe heart failure after myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi. 2006;34:582-586. Chinese.
64. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913-1918.
65. Assmus B, Schächinger V, Teupe C, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017.
66. Vulliet PR, Greeley M, Halloran SM, MacDonald KA, Kittleson MD. Intra-coronary arterial injection of mesenchymal stromal cells and microinfarction in dogs. Lancet. 2004;363:783-784.
67. Dai W, Hale SL, Kloner RA. Stem cell transplantation for the treatment of myocardial infarction. Transpl Immunol. 2005;15:91-97.
68. Reinecke H, Murry CE. Taking the death toll after cardiomyocyte grafting: a reminder of the importance of quantitative biology. J Mol Cell Cardiol. 2002;34:251-253.
69. Wang H, Zhou J, Liu Z, Wang C. Injectable cardiac tissue engineering for the treatment of myocardial infarction. J Cell Mol Med. 2010;14: 1044-1055.
70. Teng CJ, Luo J, Chiu RC, Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. J Thorac Cardiovasc Surg. 2006;132:628-632.
71. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve. 1995;18:1417-1426.
72. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;103:697-705.
73. Kehat I, Kenyagin-Karsenti D, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 2001;108:407-414.
74. Min J, Yang Y, Converso KL, et al. Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats. J Appl Physiol. 2002;92:288-296.
75. Kocher A, Schuster M, Szabolcs M, et al. Neovascularization of isch-emic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430-436.
76. Britten M, Abolmaali N, Assmus B, et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myo-cardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation. 2003;108:2212-2218.
77. Urbich C, Aicher A, Heeschen C, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005;39: 733-742.
78. Takahashi M, Li T, Suzuki R, et al. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol. 2006;291:H886-H893.
79. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR. Preconditioning mesenchymal stem cells with transforming growth factor-α improves mesenchymal stem cell-mediated cardioprotection. Shock. 2006;33:24-30.
80. Kim H, Haider H, Jiang S, Ashraf M. Ischemic preconditioning aug-ments survival of stem cells via mir-210 expression by targeting caspase-8-associated protein 2. J Biol Chem. 2009;284:33161-33168.
81. Thompson CA, Nasseri BA, Makower J, et al. Percutaneous transvenous cellular cardiomyoplasty. A novel nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol. 2003;41:1964-1971.
82. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-705.
83. Caspi O, Gepstein L. Stem cells for myocardial repair. Eur Heart J. 2006;8:E43-E54.
84. Solheim S, Seljeflot I, Lunde K, et al. Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction. Am Heart J. 2008;155: e1-e9.
85. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355:1210-1221.
86. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006;355:1199-1209.
87. Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesen-chymal stem cell in patients with acute myocardial infarction. Am J Cardiol. 2004;94:92-95.
88. Nagaya N, Fujii T, Iwase T, et al. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol. 2004;287:H2670-H2676.
89. Kinnaird T, Stabile E, Burnett MS, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004;94:678-685.
90. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213:341-347.
91. Tang YL, Zhao Q, Qin X, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005;80:229-236.
92. Dai W, Hale SL, Martin BJ, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short-and long-term effects. Circulation. 2005;112:214-223.
93. Balsam LB, Wagers AJ, Christensen JL, et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004;428:668-673.
94. Planat-Benard V, Menard C, Andre M, et al. Spontaneous cardio-myocyte differentiation from adipose tissue stroma cells. Circ Res. 2004;94:223-229.
95. Planat-Benard V, Silvestre JS, Cousin B, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation. 2004;109:656-663.
96. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001; 7:211-228.
97. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underap-preciated source of stem cells for biotechnology. Trends Biotechnol. 2006;24:150-154.
98. Miranville A, Heeschen C, Sengenes C, Curat CA, Busse R, Bouloumie A. Improvement of postnatal neovascularization by human adipose tissue derived stem cells. Circulation. 2004;110: 349-355.
99. Choi YS, Matsuda K, Dusting GJ, Morrison WA, Dilley RJ. Engineering cardiac tissue in vivo from human adipose-derived stem cells. Biomaterials. 2010;31:2236-2242.
100. Schenke-Layland K, Strem BM, Jordan MC, et al. Adipose tissue-derived cells improve cardiac function following myocardial infarction. J Surg Res. 2009;153:217-223.
101. Linke A, Muller P, Nurzynska D, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci U S A. 2005;102:8966-8971.
102. Li Z, Lee A, Huang M, et al. Imaging survival and function of transplanted cardiac resident stem cells. J Am Coll Cardiol. 2009;53: 1229-1240.
103. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378:1847-1857.
104. Joggerst SJ, Hatzopoulos AK. Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med. 2009;11:e20.
105. Murry CE, Keller G. Differentiation of embryonic stem cells to clini-cally relevant populations: lessons from embryonic development. Cell. 2008;132:661-680.
106. Kehat I, Kenyagin-Karsenti D, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 2001;108:407-414.
107. Laflamme MA, Gold J, Xu C, et al. Formation of human myocardium in the rat heart from human embryonic stem cells. Am J Pathol. 2005;167: 663-671.
108. Behfar A, Perez-Terzic C, Faustino RS, et al. Cardiopoietic program-ming of embryonic stem cells for tumor-free heart repair. J Exp Med. 2007;204:405-420.
109. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J Clin Invest. 1996;98:216-224.
110. Alperin C, Zandstra PW, Woodhouse KA. Polyurethane films seeded with embryonic stem cell-derived cardiomyocytes for use in cardiac tissue engineering applications. Biomaterials. 2005;26:7377-7386.
111. Behfar A, Zingman LV, Hodgson DM, et al. Stem cell differentiation requires a paracrine pathway in the heart. FASEB J. 2002;16: 1558-1566.
112. Behfar A, Hodgson DM, Zingman LV, Perez-Terzic C, Yamada S, Kane GC. Stem Cell Biology: Development and Plasticity. New York, NY: New York Academic Sciences; 2005.
113. Menard C, Hagege AA, Agbulut O, et al. Transplantation of cardiac-committed mouse embryonic stem cells to infarcted sheep myocardium: a preclinical study. Lancet. 2005;366:1005-1012.
114. Menard C, Grey C, Mery A, Zeineddine D, Aimond F, Puceat M. Cardiac specification of embryonic stem cells. J Cell Biochem. 2004; 93:681-687.
115. Swijnenburg RJ, Tanaka M, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation. 2005;112:I166-I172.
116. Nussbaum J, Minami E, Laflamme MA, et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 2007;21:1345-1357.
117. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451:937-942.
118. Huber I, Itzhaki I, Caspi O, et al. Identification and selection of cardio-myocytes during human embryonic stem cell differentiation. FASEB J. 2007;21:2551-2563.
119. Tomescot A, Leschik J, Bellamy V, et al. Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats. Stem Cells. 2007;25:2200-2205.
120. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872.
121. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318: 1917-1920.
122. Chin MH, Mason MJ, Xie W, et al. Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell. 2009;5:111-123.
123. Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009; 104:e30-e41.
124. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009;324: 797-801.
125. Beltrami CA, Finatom N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89:151-163.
126. Gepstein L. Derivation and potential applications of human embryonic stem cells. Circ Res. 2002;91:866-876.
127. Rubart M, Pasumarthi KB, Nakajima H, Soonpaa MH, Nakajima HO, Field LJ. Physiological coupling of donor and host cardiomyocytes after cellular transplantation. Circ Res. 2003;92:1217-1224.
128. Reinecke H, Zhang M, Bartosek T, Murry CE. Survival, integration, and differentiation of cardiomyocyte grafts: a study in normal and injured rat hearts. Circulation. 1999;100:193-202.
129. Soonpaa MH, Koh GY, Klug MG, Field LJ. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science. 1994;264:98-101.
130. Li RK, Mickle DAG, Weisel RD, et al. In vivo survival and function of transplanted rat cardiomyocytes. Circulation. 1997;96:179-187.
131. Etzion S, Battler A, Barbash IM, et al. Influence of embryonic car-diomyocyte transplantation on the progression of heart failure in a rat model of extensive myocardial infarction. J Mol Cell Cardiol. 2001;33: 1321-1330.
132. Taylor DA, Hruban R, Rodriguez ER, Goldschmidt-Clermont PJ. Cardiac chimerism as a mechanism for self-repair: does it happen and if so to what degree? Circulation. 2002;106:2-4.
133. Hocht-Zeisberg E, Kahnert H, Guan K, et al. Cellular repopulation of myocardial infarction in patients with sex-mismatched heart transplantation. Eur Heart J. 2004;25:749-758.
134. Li R, Weisel RD, Mickle DAG, et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg. 2000;119:62-68.
135. Pasumarthi KB, Field LJ. Cardiomyocyte cell cycle regulation. Circ Res. 2002;90:1044-1054.
136. Marelli D, Ma F, Chiu RC. Satellite cell implantation for neomyocar-dial regeneration. Transplant Proc. 1992;24:2995.
137. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med. 1998;4:929-933.
138. Pouly J, Hagege AA, Vilquin JT, et al. Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy? Circulation. 2004;110:1626-1631.
139. Tambara K, Sakakibara Y, Sakaguchi G, et al. Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers. Circulation. 2003;108:II259-II263.
140. Menasché P, Hagége AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet. 2001;357:279-280.
141. Reinecke H, Minami E, Poppa V, Murry CE. Evidence for fusion between cardiac and skeletal muscle cells. Circ Res. 2004;94: e56-e60.
142. Leobon B. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci U S A. 2003;100:7808-7811.
143. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol. 2000;149:731-740.
144. Gulati R, Jevremovic D, Peterson TE, et al. Diverse origin and func-tion of cells with endothelial phenotype obtained from adult human blood. Circ Res. 2003;93:1023-1025.
145. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003;23:1185-1189.
146. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progeni-tor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593-600.
147. Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation. 2003; 108:2511-2516.
148. Michaud SE, Dussault S, Haddad P, Groleau J, Rivard A. Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis. 2006;187:423-432.
149. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1-E7.
150. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104:2752-2760.
151. Berry MF, Engler AJ, Woo YJ, et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol. 2006;290:H2196-H2203.
152. Grinnemo KH, Mansson-Broberg A, Leblanc K, et al. Human mesen-chymal stem cells do not differentiate into cardiomyocytes in a cardiac ischemic xenomodel. Ann Med. 2006;38:144-153.
153. Fukuda K. Regeneration of cardiomyocytes from bone marrow: use of mesenchymal stem cell for cardiovascular tissue engineering. Cytotechnology. 2003;41:165-175.
154. Bartunek J, Croissant JD, Wijns W, et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol. 2007;292:H1095-H1104.
155. Genovese JA, Spadaccio C, Chachques E, et al. Cardiac pre-differentiation of human mesenchymal stem cells by electrostimulation. Front Biosci. 2009;14:2996-3002.
156. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93-98.
157. Tomita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 1999;100:II247-II256.
158. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, et al. Fusion of bone marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 2003;425:968-973.
159. Yoon YS, Wecker A, Heyd L, et al. Clonally expanded novel multi-potent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest. 2005;115:326-338.
160. Katritsis DG, Sotiropoulou P, Giazitzoglou E, Karvouni E, Papamichail M. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace. 2007;9:167-171.
161. Chachques JC, Trainini JC, Lago N, Cortes-Morichetti M, Schussler O, Carpentier A. Myocardial Assistance by Grafting a New Bioartificial Upgraded Myocardium (MAGNUM trial): clinical feasibility study. Ann Thorac Surg. 2008;85:901-908.
162. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autolo-gous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation. 2003;107:2294-2302.
163. Dib N, Diethrich EB, Campbell A, et al. Endoventricular transplanta-tion of allogenic skeletal myoblasts in a porcine model of myocardial infarction. J Endovasc Ther. 2002;9:313-319.
164. Davis ME, Hsieh PC, Grodzinsky AJ, Lee RT. Custom design of the cardiac microenvironment with biomaterials. Cir Res. 2005;97: 8-15.
165. Dai W, Wold LE, Dow JS, Kloner RA. Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol. 2005;46:714-719.
166. Christman KL, Fok HH, Sievers RE, Fang Q, Lee RJ. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng. 2004;10:403-409.
167. Stevens MM, George JH. Exploring and engineering the cell surface interface. Science. 2005;310:1135-1138.
168. Leor J, Tuvia S, Guetta V, et al. Intracoronary injection of in situ form-ing alginate hydrogel reverses left ventricular remodeling after myo-cardial infarction in swine. J Am Coll Cardiol. 2009;54:1014-1023.
169. Koh CJ, Atala A. Tissue engineering, stem cells, and cloning: opportunities for regenerative medicine. J Am Soc Nephrol. 2004;15: 1113-1125.
170. Landa N, Miller L, Feinberg MS, et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation. 2008;117:1388-1396.
171. Hao X, Silva EA, Mansson-Broberg A, et al. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res. 2007;75:178-185.
172. Yu J, Gu Y, Du KT, Mihardja S, Sievers RE, Lee RJ. The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials. 2009;30: 751-756.
173. Mihardja SS, Sievers RE, Lee RJ. The effect of polypyrrole on arteriogenesis in an acute rat infarct model. Biomaterials. 2008;29: 4205-4210.
174. Garner B, Georgevich A, Hodgson AJ, Liu L, Wallace GG. Polypyrrole-heparin composites as stimulus-responsive substrates for endothelial cell growth. J Biomed Mater Res. 1999;44:121-129.
175. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev. 2001;101:1869-1879.
176. Ahmed TA, Dare EV, Hincke M. Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev. 2008;14:199-215.
177. Sierra DH. Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. J Biomater Appl. 1993;7: 309-352.
178. Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol. 2004;44:654-660.
179. Yu J, Christman KL, Chin E, Sievers RE, Saeed M, Lee RJ. Restoration of left ventricular geometry and improvement of left ventricular func-tion in a rodent model of chronic ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2009;137:180-187.
180. Ryu JH, Kim IK, Cho SW, et al. Implantation of bone marrow mono-nuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium. Biomaterials. 2005;26:319-326.
181. Singelyn JM, Christman KL. Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices. J Cardiovasc Trans Res. 2010;3:478-486.
182. Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials. 2003;24:2339-2249.
183. Lu WN, Lu SH, Wang HB, et al. Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Eng Part A. 2009;15:1437-1447.
184. Chenite A, Chaput C, Wang D, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials. 2000;21: 2155-2161.
185. Yeo Y, Geng W, Ito T, Kohane DS, Burdick JA, Radisic M. Photocrosslinkable hydrogel for myocyte cell culture and injection. J Biomed Mater Res B Appl Biomater. 2007;81:312-322.
186. Maeda M, Tani S, Sano A, Fujioka K. Microstructure and release characteristics of the minipellet, a collagen-based drug delivery system for controlled release of protein drugs. J Control Release. 1999;62: 313-324.
187. Kutschka I, Chen IY, Kofidis T, et al. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improve-ment of ischemic rat hearts. Circulation. 2006;114:I167-I173.
188. Kutschka I, Chen IY, Kofidis T, et al. In vivo optical bioluminescence imaging of collagen-supported cardiac cell grafts. J Heart Lung Transplant. 2007;3:273-280.
189. Zhang Y, Thorn S, DaSilva JN, et al. Collagen-based matrices improve the delivery of transplanted circulating progenitor cells: development and demonstration by ex vivo radionuclide cell labeling and in vivo tracking with positron-emission tomography. Circ Cardiovasc Imaging. 2008;3:197-204.
190. Nelson DM, Ma Z, Fujimoto KL, Hashizume R, Wagner WR. Intra-myocardial biomaterial injection therapy in the treatment of heart failure: materials, outcomes and challenges. Acta Biomater. 2011;7: 1-15.
191. Huang NF, Yu J, Sievers R, Li S, Lee RJ. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng. 2005; 11:1860-1866.
192. Kofidis T, de Bruin JL, Hoyt G, et al. Injectable bioartificial myocardial tissue for large-scale intramural cell transfer and functional recovery of injured heart muscle. J Thorac Cardiovasc Surg. 2004;128:571-578.
193. Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC. Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation. 2005;112:I173-I177.
194. Albini A, Melchiori A, Garofalo A, et al. Matrigel promotes retinoblastoma cell growth in vitro and in vivo. Int J Cancer. 1992;52: 234-240.
195. Davis ME, Motion JP, Narmoneva DA, et al. Injectable self assem-bling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation. 2005;111:442-450.
196. Gilbert TW, Sellaro TL, Badylak SF. Decellularization of tissues and organs. Biomaterials. 2006;27:3675-3683.
197. Singelyn JM, DeQuach JA, Seif-Naraghi SB, Littlefield RB, Schup-Magoffin PJ, Christman KL. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials. 2009;30:5409-5416.
198. Seif-Naraghi SB, Salvatore MA, Schup-Magoffin PJ, Hu DP, Christman KL. Design and characterization of an injectable pericardial matrix gel: a potentially autologous scaffold for cardiac tissue engineering. Tissue Eng Part A. 2010;16:2017-2027.
199. Badylak SF. The extracellular matrix as a biologic scaffold material. Biomaterials. 2007;28:3587-3593.
200. Ott HC, Matthiesen TS, Goh SK, et al. Perfusion decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med. 2008;14:213-221.
201. Zhao ZQ, Puskas JD, Xu D, et al. Improvement in cardiac function with small intestine extracellular matrix is associated with recruitment of C-kit cells, myofibroblasts, and macrophages after myocardial infarction. J Am Coll Cardiol. 2010;55:1250-1261.
202. Badylak SF, Obermiller J, Geddes L, Matheny R. Extracellular matrix for myocardial repair. Heart Surg Forum. 2002;6:E20-E26.
203. Mukherjee R, Zavadzkas JA, Saunders SM, et al. Targeted myocardial microinjection of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg. 2008;86:1268-1276.
204. Zhang G, Hu Q, Braunlin EA, Suggs LJ, Zhang J. Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix. Tissue Eng Part A. 2008;14:1025-1036.
205. Narmoneva DA, Vukmirovic R, Davis ME, Kamm RD, Lee RT. Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation. 2004;110:962-968.
206. Holmes TC. Novel peptide-based biomaterial scaffolds for tissue engineering. Trends Biotechnol. 2002;20:16-21.
207. Hsieh PC, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local con-trolled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation. 2006;114:637-644.
208. Hsieh PC, Davis ME, Gannon J, MacGillivray C, Lee RT. Controlled delivery of PDGF-BB for myocardial protection using inject-able self-assembling peptide nanofibers. J Clin Invest. 2006;116: 237-248.
209. Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation. 2007;116:1683-1692.
210. Dobner S, Bezuidenhout D, Govender P, Zilla P, Davies N. A synthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling. J Card Fail. 2009; 15:629-636.
211. Fujimoto KL, Ma Z, Nelson DM, et al. Synthesis, characterization and therapeutic efficacy of a biodegradable, thermoresponsive hydrogel designed for application in chronic infarcted myocardium. Biomaterials. 2009;30:4357-4368.
212. Purcell BP, Elser JA, Mu A, Margulies KB, Burdick JA. Synergistic effects of SDF-1α chemokine and hyaluronic acid release from degrad-able hydrogels on directing bone marrow derived cell homing to the myocardium. Biomaterials. 2012;33:7849-7857.
213. Chi NH, Yang MC, Chung TW, Chen JY, Chou NK, Wang SS. Cardiac repair achieved by bone marrow mesenchymal stem cells/silk fibroin/hyaluronic acid patches in a rat of myocardial infarction model. Biomaterials. 2012;33:5541-5551.
214. Wang H, Liu Z, Li D, et al. Injectable biodegradable hydrogels for embryonic stem cell transplantation: improved cardiac remodelling and function of myocardial infarction. J Cell Mol Med. 2012;16: 1310-1320.
215. Davis ME, Hsieh PC, Takahashi T, et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A. 2006;103:8155-8160.
216. Padin-Iruegas ME, Misao Y, Davis ME, et al. Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation. 2009;120:876-887.
217. Kawada H, Fujita J, Kinjo K, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood. 2004;104:3581-3587.
218. Ohtsuka M, Takano H, Zou Y, et al. Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J. 2004;18:851-853.
219. Casilde S, Sharon LH, Carolyn L, Robert AK. Granulocyte colony-stimulating factor and stem cell factor improve contractile reserve of the infarcted left ventricle independent of restoring muscle mass. J Am Coll Cardiol. 2005;46:1662-1669.
220. Lee KY, Peters MC, Anderson KW, Mooney DJ. Controlled growth factor release from synthetic extracellular matrices. Nature. 2000;408: 998-1000.
221. Iwakura A, Fujita M, Kataoka K, et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels. 2003;18: 93-99.
222. Christman KL, Fang Q, Yee MS, Johnson KR, Sievers RE, Lee RJ. Enhanced neovasculature formation in ischemic myocardium follow-ing delivery of pleiotrophin plasmid in a biopolymer. Biomaterials. 2005;26:1139-1144.
223. Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G, Cohen S. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res. 2003;65A:489-497.
224. Urech L, Bittermann AG, Hubbell JA, Hall H. Mechanical properties, proteolytic degradability and biological modifications affect angiogenic process extension into native and modified fibrin matrices in vitro. Biomaterials. 2005;26:1369-1379.
225. Semler EJ, Ranucci CS, Moghe PV. Mechanochemical manipulation of hepatocyte aggregation can selectively induce or repress liver-specific function. Biotechnol Bioeng. 2000;69:359-369.
226. Barocas VH, Moon AG, Tranquillo RT. The fibroblast populated microsphere assay of cell traction force-part 2: measurement of the cell traction coefficient. J Biomech Eng. 1995;117:161-170.
227. Stile RA, Chung E, Burghardt WR, Healy KE. Poly(N-isopropylacrylamide)-based semi-interpenetrating polymer networks for tissue engineering applications. Effects of linear poly(acrylic acid) chains on rheology. J Biomater Sci Polym Ed. 2004;15:865-878.
228. Kim S, Healy KE. Synthesis and characterization of injectable poly(N-isopropylacrylamideco-acrylic acid) hydrogels with proteolytically degradable cross-links. Biomacromolecules. 2003;4:1214-1223.
229. Stokke BT, Draget KI, Smidsrod O, Yuguchi Y, Urakawa H, Kajiwara K. Small-angle X-ray scattering and rheological characteriza-tion of alginate gels. 1. Ca-alginate gels. Macromolecules. 2000;33: 1853-1863.
230. Rizzi SC, Ehrbar M, Halstenberg S, et al. Recombinant protein-co-PEG networks as cell-adhesive and proteolytically degradable hydrogel matrixes part II: biofunctional characteristics. Biomacromolecules. 2006;7:3019-3029.
231. Omens JH. Stress and strain as regulators of myocardial growth. Prog Biophys Mol Biol. 1998;69:559-572.
232. Eschenhagen T, Didie M, Heubach J, Ravens U, Zimmermann WH. Cardiac tissue engineering. Transpl Immunol. 2002;9:315-321.